Both in Pharmaceuticals
Apimeds Pharmaceuticals US vs Onconetix
Over the past year APUS returned −89.3% and ONCO returned −99.6%; their daily moves had a correlation of -0.20.
APUS −89.3% ONCO −99.6%Growth of $1, one year, split-adjusted
| Metric | APUS | ONCO |
|---|---|---|
| Price | $2.92 | $0.6583 |
| Market cap | $4.4M | $3.9M |
| Today | −1.68% | +15.69% |
| 1 month | −59.0% | −0.4% |
| 6 months | −85.0% | −85.4% |
| Year to date | −82.2% | −99.2% |
| 1 year | — | −99.6% |
| Revenue growth (YoY) | — | −83.9% |
| Gross margin | — | 25.1% |
| Net margin | — | −16748.3% |
| P/E (TTM) | — | — |
| Price / sales | — | 6.0× |
| Net cash | -$8.6M | $5.8M |
| Dividend yield | — | — |
| Volatility (60d) | 263.3% | 159.7% |
| Short % of float | 0.9% | 7.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).